RU2018111298A - Биспецифическое антитело, которое специфично связывается с IV и II cубдоменами внеклеточного домена HER2 человека - Google Patents
Биспецифическое антитело, которое специфично связывается с IV и II cубдоменами внеклеточного домена HER2 человека Download PDFInfo
- Publication number
- RU2018111298A RU2018111298A RU2018111298A RU2018111298A RU2018111298A RU 2018111298 A RU2018111298 A RU 2018111298A RU 2018111298 A RU2018111298 A RU 2018111298A RU 2018111298 A RU2018111298 A RU 2018111298A RU 2018111298 A RU2018111298 A RU 2018111298A
- Authority
- RU
- Russia
- Prior art keywords
- cancer
- her2
- antibody
- subdomain
- extracellular domain
- Prior art date
Links
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 title claims 20
- 102000051957 human ERBB2 Human genes 0.000 title claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 18
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 9
- 206010006187 Breast cancer Diseases 0.000 claims 8
- 208000026310 Breast neoplasm Diseases 0.000 claims 8
- 206010009944 Colon cancer Diseases 0.000 claims 8
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 230000001404 mediated effect Effects 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims 4
- 206010014733 Endometrial cancer Diseases 0.000 claims 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 4
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 4
- 101000606741 Homo sapiens Phosphoribosylglycinamide formyltransferase Proteins 0.000 claims 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 4
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 4
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims 4
- 206010034811 Pharyngeal cancer Diseases 0.000 claims 4
- 102100039654 Phosphoribosylglycinamide formyltransferase Human genes 0.000 claims 4
- 206010038389 Renal cancer Diseases 0.000 claims 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims 4
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 4
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 201000010881 cervical cancer Diseases 0.000 claims 4
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 4
- 201000004101 esophageal cancer Diseases 0.000 claims 4
- 206010017758 gastric cancer Diseases 0.000 claims 4
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 4
- 201000010982 kidney cancer Diseases 0.000 claims 4
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 4
- 201000001441 melanoma Diseases 0.000 claims 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 4
- 201000002528 pancreatic cancer Diseases 0.000 claims 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 4
- 201000000849 skin cancer Diseases 0.000 claims 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 4
- 206010046766 uterine cancer Diseases 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 3
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 230000000259 anti-tumor effect Effects 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 229960000575 trastuzumab Drugs 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- -1 antibody Substances 0.000 claims 1
- 239000013059 antihormonal agent Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 230000009466 transformation Effects 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2018111298A RU2018111298A (ru) | 2018-03-29 | 2018-03-29 | Биспецифическое антитело, которое специфично связывается с IV и II cубдоменами внеклеточного домена HER2 человека |
| PCT/RU2019/050037 WO2019190359A1 (fr) | 2018-03-29 | 2019-03-28 | Anticorps bispécifique qui se lie de manière spécifique aux sous-domaines iv et ii du domaine extracellulaire her2 de l'humain |
| TW108111247A TW202003038A (zh) | 2018-03-29 | 2019-03-29 | 特異性結合人ｈｅｒ２的細胞外結構域的亞結構域ｉｖ和ｉｉ的雙特異性抗體 |
| UY38168A UY38168A (es) | 2018-03-29 | 2019-03-29 | Anticuerpo bi-específico que se une a los subdominios iv y ii del dominio extracelular del her2 humano |
| ARP190100823A AR115311A1 (es) | 2018-03-29 | 2019-03-29 | Anticuerpo biespecífico que específicamente se une a los subdominios iv y ii del dominio extracelular del her2 humano |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2018111298A RU2018111298A (ru) | 2018-03-29 | 2018-03-29 | Биспецифическое антитело, которое специфично связывается с IV и II cубдоменами внеклеточного домена HER2 человека |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2018111298A true RU2018111298A (ru) | 2019-10-01 |
Family
ID=68058434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018111298A RU2018111298A (ru) | 2018-03-29 | 2018-03-29 | Биспецифическое антитело, которое специфично связывается с IV и II cубдоменами внеклеточного домена HER2 человека |
Country Status (5)
| Country | Link |
|---|---|
| AR (1) | AR115311A1 (fr) |
| RU (1) | RU2018111298A (fr) |
| TW (1) | TW202003038A (fr) |
| UY (1) | UY38168A (fr) |
| WO (1) | WO2019190359A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119462944B (zh) * | 2024-12-02 | 2025-12-09 | 中国人民解放军军事科学院军事医学研究院 | 人表皮生长因子受体2单克隆抗体及其用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2865597A1 (fr) * | 2012-03-16 | 2013-09-19 | Covagen Ag | Nouvelles molecules de liaison a activite antineoplasique |
| PL3074424T3 (pl) * | 2013-11-27 | 2025-06-09 | Zymeworks Bc Inc. | Bispecyficzne konstrukty wiążące antygen ukierunkowane na her2 |
-
2018
- 2018-03-29 RU RU2018111298A patent/RU2018111298A/ru not_active Application Discontinuation
-
2019
- 2019-03-28 WO PCT/RU2019/050037 patent/WO2019190359A1/fr not_active Ceased
- 2019-03-29 AR ARP190100823A patent/AR115311A1/es unknown
- 2019-03-29 UY UY38168A patent/UY38168A/es not_active Application Discontinuation
- 2019-03-29 TW TW108111247A patent/TW202003038A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR115311A1 (es) | 2020-12-23 |
| UY38168A (es) | 2019-10-31 |
| WO2019190359A1 (fr) | 2019-10-03 |
| TW202003038A (zh) | 2020-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210277109A1 (en) | Anti-ror1 antibodies and methods of making and using thereof | |
| JP2019536470A5 (fr) | ||
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| CN112830969B (zh) | 一种特异性结合人Claudin18.2的单克隆抗体及包含其的药物和试剂盒 | |
| TWI797609B (zh) | 抗pd-1和pd-l1的四價雙特異性抗體 | |
| JP2024016024A5 (fr) | ||
| JP2023522630A (ja) | 抗ｆｌｔ３抗体及び組成物 | |
| JP2019512210A5 (fr) | ||
| KR102773176B1 (ko) | 암 치료용 안티-서비빈 항체 | |
| RU2019116638A (ru) | Биспецифические полипептиды к gitr и ctla-4 | |
| CN107108735B (zh) | 新型egfrviii抗体和包含所述抗体的组合物 | |
| RU2018111298A (ru) | Биспецифическое антитело, которое специфично связывается с IV и II cубдоменами внеклеточного домена HER2 человека | |
| JPWO2019170898A5 (fr) | ||
| WO2024175093A1 (fr) | Anticorps, fragments de liaison à l'antigène et procédés d'utilisation | |
| CN115279791A (zh) | 靶向her2的抗原结合构建体及用途 | |
| JPWO2022067262A5 (fr) | ||
| JPWO2020218951A5 (fr) | ||
| JPWO2021063201A5 (fr) | ||
| JPWO2021247769A5 (fr) | ||
| JPWO2022152290A5 (fr) | ||
| JPWO2019170885A5 (fr) | ||
| WO2024088388A1 (fr) | Conjugués ligand-médicament cytotoxique et leurs utilisations pharmaceutiques | |
| JP7568326B2 (ja) | 二重特異抗体またはその抗原結合断片、及びそれを製造する方法 | |
| JPWO2021173832A5 (fr) | ||
| RU2020138026A (ru) | Cd3-специфические антитела и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20210330 |